HIV integrase inhibitors: a new era in the treatment of HIV

Bibliography

• Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-50
   PubMed Web of Science ®Google Scholar
• Grinstein B, De Castro N, Arnold V, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014;14(6):459-67
   PubMedGoogle Scholar
• Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55:39-48
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011;53:807-16
   PubMed Web of Science ®Google Scholar
• DeJesus E, Lazzarin A, Lennox AJ, et al. Metabolic profiles and body composition changes in treatment-naïve HIV-infected patients treated with raltegravir 400 mg bid-based vs. Efavirenz 600 mg qhs-based Combination Therapy: 48-Week Data. ICAAC 2009 H-329
   Google Scholar
• Landovitz RJ, Ribaudo HJ, Ofotokun I, et al. Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir with FTC/Tenofovir: ACTG 5257. Abstract 85, CROI 2014, Boston, MA, March 3-6, 2014.
   Google Scholar
• Eron JJJr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011;11:907-15
   PubMed Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375(9712):396-407
   PubMed Web of Science ®Google Scholar
• Martínez E, D’Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012;26:2315-26
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 2012;26:475-81
   PubMed Web of Science ®Google Scholar
• Lake JE, McComsey GA, Hulgan TM, et al. A Randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in hiv-infected women with lipohypertrophy. AIDS Patient Care STDS 2012;26(9):532-40
   PubMedGoogle Scholar
• Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543-7
   PubMed Web of Science ®Google Scholar
• Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013;13:587-96
   PubMed Web of Science ®Google Scholar
• Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. Lancet Infect Dis 2014;14(7):590-9
   PubMed Web of Science ®Google Scholar
• Arribas J, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014;14(7):581-9
   PubMed Web of Science ®Google Scholar
• Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25(6):F7-12
   PubMed Web of Science ®Google Scholar
• Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents regimens. Available from: http://aidsinfo.nih.gov/guidelines [Last accessed 4 July 2014]
   Google Scholar
• Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012;379(9835):2439-48
   PubMed Web of Science ®Google Scholar
• Zolopa A, Sax PE, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;63(1):96-100
   PubMed Web of Science ®Google Scholar
• Wohl DA, Cohen C, Gallant JE, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65(3):e118-20
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012;379(9835):2429-38
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013;62(5):483-6
   PubMed Web of Science ®Google Scholar
• Clumeck N, Molina JM, Henry K, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 2014;65(3):e121-4
   PubMed Web of Science ®Google Scholar
• Molina JM, LaMarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012;12(1):27-35
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-300
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429-41
   PubMed Web of Science ®Google Scholar
• Llibre JM, Pulido F, Garcia F, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev 2015;17(1):56-64
   PubMed Web of Science ®Google Scholar
• Blanco Arevalo JL, Whitlock GG. Dolutegravir: an exciting new kid on the block. Expert Opin Pharmacother 2014;15(4):573-82
   PubMed Web of Science ®Google Scholar
• Walmsley S, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 Infection. N Engl J Med 2013;369:1807-18
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43
   PubMed Web of Science ®Google Scholar
• Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experience, intergrase-inhibitor-naïve adults with HIV: week 48 results from the randomized, double-blind, non-inferiority SAILING study. Lancet 2013;382(9893):700-8
   PubMed Web of Science ®Google Scholar
• Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in Antiretroviral-Experienced Patients with Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-week Results of the Phase III VIKING-3 Study. J Infect Dis 2014;210(3):354-62
   PubMed Web of Science ®Google Scholar
• Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomized open-label phase 3b study. Lancet 2014;383(9936):2222-31
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010;7:e1000321
   PubMed Web of Science ®Google Scholar
• McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;50:912-19
   PubMed Web of Science ®Google Scholar
• Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed 48-week study. Antivir Ther 2012;17:355-6
   PubMedGoogle Scholar
• Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral prenetration on cognitive functioning in the ALLRT cohort. AIDS 2011;25(3):357-65
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Gisslén M, Sudich S, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS ONE 2009;4:e6877
   PubMed Web of Science ®Google Scholar
• Letendre S, Mills A, Tashima K, et al. ING116070: A study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1–infected, antiretroviral therapy–naive subjects. Clin Infect Dis 2014;59(7):1032-7
   PubMed Web of Science ®Google Scholar
• Sax P, Zolopa A, Brar I, et al. Tenofovir alafenamide vs tenofovir disoproxil fumarate in single Tablet régimen for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014;67:52-8
   PubMedGoogle Scholar
• Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010;24(11):1697-707
   PubMed Web of Science ®Google Scholar
• Blanco JL, Montaner J, Marconi VC, et al. Lower Prevalence of Drug Resistance Mutations at First-Line Virological Failure to First-line Therapy with Atripla® vs. Tenofovir+Emtricitabine/Lamivudine+Efavirenz Administered on a Multiple Tablet Therapy. AIDS 2014;28(17):2531-9
   PubMed Web of Science ®Google Scholar
• German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012;61(1):32-40
   PubMed Web of Science ®Google Scholar
• Available from: http://www.gilead.com/∼/media/Files/pdfs/medicines/hiv/stribild/stribild_pi.pdf
   Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002572/WC500153014.pdf
   Google Scholar
• Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 2013;57(10):4982-9
   PubMed Web of Science ®Google Scholar
• Maggi P, Montinaro V, Rusconi S, et al. The problem of renal function monitoring in patients treated with the novel antiretroviral drugs. HIV Clin Trials 2014;15(3):87-91
   PubMed Web of Science ®Google Scholar
• Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011;55(10):4552-9
   PubMed Web of Science ®Google Scholar
• Weller S, Chen S, Bolard J, et al. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr 2014;66:393-8
   PubMed Web of Science ®Google Scholar
• Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013;41(2):353-61
   PubMed Web of Science ®Google Scholar